Some of these drugs have been already available in trials for NSCLC patients and specifically target MET (telisotuzumab vedotin), HER2 (trastuzumab deruxtecan), HER3 (patritumab deruxtecan), TROP2 (datopotamab deruxtecan and SKB264). Here, MET is linked to non-small cell lung carcinoma.